Now Reading: Dr Reddy’s gets Brazil approval for generic semaglutide injection
-
01
Dr Reddy’s gets Brazil approval for generic semaglutide injection
Dr Reddy’s gets Brazil approval for generic semaglutide injection
The Story in Brief
Dr Reddy’s Laboratories has received marketing authorisation from Brazil’s ANVISA for its generic semaglutide injection, the company said on 5 November. The drug, a generic version of Novo Nordisk’s Ozempic, will be available as a pre-filled, multi-dose injectable pen in 2 mg and 4 mg doses for once-weekly use in adults with insufficiently controlled type 2 diabetes.
Brazil has 16.6 million adults aged 20 to 79 living with diabetes, ranking sixth globally, and the semaglutide market there is estimated at about $244.6 million. MV Ramana, CEO of Global Generics at Dr Reddy’s, said the company plans to launch the product in Brazil with partner Aché, adding that the approval builds on its broader semaglutide strategy. Business Standard notes that ANVISA had denied the application in April 2026, and that Dr Reddy’s had recalled a batch of the drug in Canada earlier this year and plans a relaunch there in the current quarter.
Indian Opinion Analysis
All four outlets, CNBC TV18, The Economic Times, The Hindu Business Line, and Business Standard, report the ANVISA approval as a standard corporate disclosure from Dr Reddy’s, with near-identical facts: the two-dose presentation, the $244.6 million market estimate, and the partnership with Aché. The only framing difference comes from Business Standard, which adds two pieces of context the others omit: that ANVISA had earlier denied the application in April 2026, and that Dr Reddy’s had recalled a batch of generic semaglutide in Canada earlier this year and plans a relaunch in the current quarter. While the other outlets treat the approval as a fresh positive step, Business Standard implicitly reminds readers of the regulatory and quality setbacks the company has faced.
Coverage: 4 sources, 4 neutral
Sources (4): cnbctv18.com (neutral report), economictimes.indiatimes.com (neutral report), thehindubusinessline.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Methodology and corrections.
Update, 5 November 2026: this story now draws on 4 sources.
